仙琚製藥(002332.SZ):舒更葡糖鈉藥品註冊申請獲得受理
格隆匯 8 月 7日丨仙琚製藥(002332.SZ)公佈,公司於近日收到國家藥品監督管理局下發的舒更葡糖鈉原料藥及舒更葡糖鈉注射液境內生產藥品註冊受理通知書。
舒更葡糖鈉注射液原研製劑(商品名布瑞亭,Bridion)由英國Merck Sharp & Dohme Limited(默沙東)公司首家研製而成。舒更葡糖鈉注射液製劑中的活性成分舒更葡糖是一種經修飾的γ-環糊精,可以選擇性結合神經肌肉形成複合物,阻斷神經肌肉阻滯藥物羅庫溴銨或維庫溴銨,進而降低在神經肌肉接頭處與煙鹼受體相結合的神經肌肉阻滯藥物的數量,由此拮抗由羅庫溴銨或維庫溴銨誘導的神經肌肉阻滯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.